PrEP (pre-exposure prophylaxis) is HIV medication taken before a possible exposure by people who are HIV-negative and at ongoing risk. PEP (post-exposure prophylaxis) is a short course of HIV medication started within 72 hours after a single possible exposure and taken for 28 days. PrEP is ongoing prevention; PEP is emergency prevention.
Nurses meet patients who could benefit from HIV prevention in almost every setting: emergency departments, clinics, urgent care, sexual health services, and occupational health after a needlestick. Knowing the difference between PrEP and PEP, and being comfortable bringing them up, can prevent infections. This guide covers who each option is for, timing, current regimens, testing, occupational exposures, and patient teaching.
Key Takeaways
- PrEP is taken before exposure by HIV-negative people at ongoing risk; PEP is taken after a single possible exposure.
- PEP must start within 72 hours of exposure (the sooner the better) and continues for 28 days.
- PrEP options include daily oral pills and long-acting injections.
- Both require HIV testing, and PrEP requires ongoing testing and follow-up.
- Healthcare workers with a needlestick or other exposure should report it immediately so PEP can be considered within hours.
PrEP vs PEP at a Glance
| Feature | PrEP | PEP |
|---|---|---|
| Stands for | Pre-exposure prophylaxis | Post-exposure prophylaxis |
| When it’s used | Before possible exposure, on an ongoing basis | After a single possible exposure |
| Who it’s for | HIV-negative people at ongoing risk | HIV-negative people with a recent possible exposure |
| Timing | Started in advance and continued while risk continues | Started within 72 hours of exposure |
| Duration | Ongoing | 28 days |
| Form | Daily oral pill or long-acting injection | Oral multi-drug antiretroviral regimen |
| Follow-up | Regular HIV and lab testing | HIV testing at baseline and after the course |
What Is PrEP?
PrEP is medication that HIV-negative people take to prevent getting HIV. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex by about 99% when taken as prescribed, and from injection drug use by at least 74%. Options in the United States include:
- Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), available as brand and generic.
- Daily oral tenofovir alafenamide/emtricitabine (TAF/FTC), which is not approved for people whose risk comes from receptive vaginal sex.
- Injectable cabotegravir, given every two months after initiation injections.
- Injectable lenacapavir, approved by the FDA in 2025 and given twice a year after initiation.
Before starting PrEP, the patient needs a negative HIV test, because PrEP alone is not treatment for HIV and could lead to drug resistance if HIV is already present. Ongoing PrEP requires regular HIV testing and follow-up visits, plus kidney function monitoring for oral tenofovir-based regimens.
Who might benefit from PrEP?
The CDC recommends that all sexually active adults and adolescents be informed about PrEP. It may be especially beneficial for people who have a sexual partner with HIV whose viral load is not suppressed, who do not consistently use condoms, who were recently diagnosed with a bacterial sexually transmitted infection, who inject drugs and share equipment, or who have used PEP repeatedly.
What Is PEP?
PEP is a short course of antiretroviral medication taken after a possible exposure to HIV. It must be started within 72 hours of the exposure, and it works best the sooner it is started. The patient takes a three-drug regimen every day for 28 days. Common situations include:
- Condomless sex with a partner who has HIV or whose status is unknown
- A condom breaking during sex
- Sexual assault
- Sharing needles or other drug equipment
- Occupational exposure, such as a needlestick or a splash to mucous membranes
PEP is not meant for regular use. Anyone who needs PEP more than once should be offered PrEP, and patients can often transition from PEP directly to PrEP if their risk continues.
Occupational Exposure: What Nurses Should Do After a Needlestick
The average risk of HIV transmission after a percutaneous exposure to HIV-infected blood is estimated at about 0.3%, but that risk is preventable. If you have a needlestick or blood or body fluid exposure:
- Wash needlesticks and cuts with soap and water; flush splashes to the nose, mouth, or skin with water; irrigate eyes with clean water or saline.
- Report immediately to your supervisor and employee health or the emergency department. Do not wait until the end of the shift.
- Get evaluated quickly. If PEP is recommended, it should ideally start within hours, not days.
- Follow up for testing and to complete the full course if prescribed.
Prevention comes first: use safety-engineered devices, never recap needles, dispose of sharps immediately, and apply standard precautions with every patient.
Access in California
Under California law (SB 159), pharmacists who complete required training may furnish PEP and up to a 60-day supply of PrEP without a prescription, after which the patient is linked to a provider for ongoing care. This can make same-day access easier, especially for PEP, where timing is critical.
The Nurse’s Role: Patient Teaching and Communication
- Ask without judgment. Use neutral, open questions: “Some of my patients want to know about ways to prevent HIV. Would that be helpful to talk about?”
- Explain the time window for PEP clearly and urgently: 72 hours is the outer limit.
- Teach adherence. Daily oral PrEP works best when taken consistently; injection appointments must be kept on schedule.
- Review side effects such as nausea or headache, which are usually mild and short-lived.
- Remind patients that PrEP and PEP do not protect against other sexually transmitted infections or pregnancy.
- Confirm understanding with teach-back and document the education.
Patients may feel embarrassed or worried about being judged. The skills in therapeutic communication in nursing and cultural competence in nursing help make these conversations easier.
Expand Your HIV Knowledge
For a deeper review of HIV screening, treatment, and long-term care, take HIV Primary Care: A Review. It is included in our California RN CE package.
Frequently Asked Questions
What is the difference between PrEP and PEP?
PrEP is HIV medication taken before possible exposure, on an ongoing basis, by HIV-negative people at risk. PEP is a 28-day course of HIV medication started within 72 hours after a single possible exposure. PrEP is routine prevention; PEP is emergency prevention.
How soon after exposure must PEP be started?
PEP must be started within 72 hours of a possible HIV exposure, and it is most effective the sooner it is started. After 72 hours, PEP is generally not recommended.
How effective is PrEP?
According to the CDC, PrEP reduces the risk of getting HIV from sex by about 99% when taken as prescribed, and reduces the risk from injection drug use by at least 74%.
Is there an injectable form of PrEP?
Yes. Long-acting injectable cabotegravir is given every two months after initiation, and injectable lenacapavir, approved by the FDA in 2025, is given twice a year after initiation. Both require regular HIV testing.
What should a nurse do after a needlestick injury?
Wash the area with soap and water, report the exposure immediately to a supervisor and employee health, and get evaluated right away so PEP can be started within hours if it is recommended. Complete all follow-up testing.
Sources and Further Reading
- Centers for Disease Control and Prevention (CDC), Preexposure Prophylaxis for the Prevention of HIV Infection in the United States: Clinical Practice Guideline
- Centers for Disease Control and Prevention (CDC), Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV
- U.S. Public Health Service, Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
- California Senate Bill 159 (2019), pharmacist furnishing of PrEP and PEP
This article was prepared under our Editorial and Review Policy. It is for educational purposes and does not replace official guidance from your licensing board, employer policy, or a clinician’s judgment.



